Alcon Gains FDA Approval for Brytly, First Nonprescription Apraclonidine Eye Drop

Alcon's FDA approval of Brytly (apraclonidine ophthalmic solution, 0.125%) on October 16, 2026, introduces the first nonprescription apraclonidine eye drop to the U.S. market, a development that carries labeling, formulation, and regulatory classification implications for any manufacturer tracking the OTC drug access pipeline.

Apraclonidine at higher concentrations has an established prescription history in glaucoma management and laser ophthalmic procedures. The 0.125% concentration in Brytly sits below that therapeutic threshold, enabling the nonprescription pathway under 21 CFR Part 330 OTC monograph and Drug Facts labeling requirements. Regulatory affairs teams should note that the approval reflects FDA's stated priority, articulated by CDER Director Mike Davis, M.D., Ph.D., of fostering competition and expanding nonprescription drug availability as a public health strategy, not a one-off approval.

From a labeling compliance standpoint, the approved Drug Facts label carries specific use restrictions: indicated for adults and children 12 years and older, maximum two applications per day, and a three-day duration limit before physician referral is required. Contact lens guidance is also codified, removal before instillation, a minimum 10-minute wait before reinsertion, and a five-minute interval between concurrent ophthalmic products. QA and regulatory leads preparing OTC submissions or label reviews should treat these parameters as the agency's current benchmark for alpha-agonist ophthalmic products in the nonprescription space.

The broader signal for pipeline and regulatory strategy is the agency's active posture on Rx-to-OTC switches and new nonprescription approvals. FDA's Public Health Pillars, cited in the approval announcement, explicitly prioritize affordable medicine access and market competition, framing that suggests continued receptivity to well-characterized molecules seeking nonprescription reclassification, provided the safety and labeling data support self-selection without provider involvement.

Alcon's Brytly launch will test real-world consumer compliance with the Drug Facts label's contraindication and stop-use language, a dataset that will carry weight in any post-market surveillance review and could inform future nonprescription ophthalmic submissions across the industry.

Source: U.S. Food and Drug Administration via FDA.gov Drugs RSS Feed, October 16, 2026.